RAMP3 modifies the GLP-1 receptor to bias signaling toward calcium mobilization and enhanced insulin secretion, potentially enabling more targeted GLP-1 drugs with fewer side effects.
Signaling bias toward Ca2+RAMP3 shifted GLP-1 receptor signaling from cAMP toward calcium mobilization, enhancing insulin secretion in pancreatic beta cells
What the researchers found
RAMP3 interacts with the GLP-1 receptor, biasing signaling toward Ca2+ mobilization (away from cAMP), which enhanced glucose-stimulated insulin secretion in pancreatic cells.
Why it matters
Current GLP-1 drugs activate the receptor the same way everywhere in the body, causing side effects. RAMP3 shows a way to achieve tissue-selective signaling that could lead to better-tolerated medications.
The numbers in context
RAMP3 reduced Gαs coupling, increased Gαq and Gαi coupling. Shifted signaling from cAMP to Ca2+ mobilization. Enhanced glucose-stimulated insulin secretion in RAMP3-overexpressing cells.
How the study worked
Cell-based laboratory study examining RAMP3-GLP-1 receptor interaction, signaling bias, surface expression, and functional effects on insulin secretion.
Who was studied
Not applicable (cell-based receptor pharmacology)
What this study cannot tell us
Cell-based study — the RAMP3 effects on GLP-1 signaling have not been confirmed in animal models or humans. The therapeutic potential is theoretical at this stage.
How to read the evidence
In vitro cell-based study providing mechanistic insight. Strong for understanding receptor biology but requires in vivo validation before therapeutic implications can be confirmed.
When this study was published
Published in 2025, representing cutting-edge receptor pharmacology research with implications for next-generation GLP-1 drug design.
The bigger picture
RAMPs represent a new frontier in GPCR drug design. By understanding how these accessory proteins modify receptor signaling, scientists could develop next-generation GLP-1 drugs with improved tissue selectivity and safety profiles.
Questions still open
- Can RAMP3-selective GLP-1 agonists be designed that retain metabolic benefits while avoiding GI side effects?
- How does RAMP3 expression vary across different tissues and disease states?
Common questions
What are RAMPs and why do they matter for GLP-1 drugs?
Could this lead to GLP-1 drugs without nausea?
Read the original research
Receptor activity-modifying protein 3 enhances GLP-1-mediated insulin secretion.
The Journal of biological chemistry, 301(10), 110604
Citation
Pearce, Abigail; Kumari, Poonam; Sisk, Claudia M; Harris, Matthew; Yeung, Ho Yan; Winfield, Sabrina; Caron, Kathleen M; Ladds, Graham. (2025). Receptor activity-modifying protein 3 enhances GLP-1-mediated insulin secretion.. The Journal of biological chemistry, 301(10), 110604. https://doi.org/10.1016/j.jbc.2025.110604